|1.||Malik, Fady I: 5 articles (11/2015 - 07/2010)|
|2.||Lee, Jacqueline H: 3 articles (01/2015 - 08/2011)|
|3.||Saikali, Khalil G: 3 articles (01/2015 - 08/2011)|
|4.||Wolff, Andrew A: 3 articles (01/2015 - 08/2011)|
|5.||Cleland, John G F: 3 articles (08/2011 - 11/2006)|
|6.||Teerlink, John R: 3 articles (08/2011 - 12/2009)|
|7.||Solaro, R John: 2 articles (10/2015 - 04/2009)|
|8.||Greenberg, Barry H: 2 articles (01/2015 - 08/2011)|
|9.||Shaburishvili, Tamaz: 2 articles (01/2015 - 08/2011)|
|10.||Wasserman, Scott M: 2 articles (01/2015 - 08/2011)|
11/01/2015 - "Data from 3 clinical trials of omecamtiv mecarbil in healthy volunteers and patients with stable heart failure (HF) were analyzed using a nonlinear mixed-effects model to investigate omecamtiv mecarbil's pharmacokinetics and relationship between plasma concentration and systolic ejection time (SET) and Doppler-derived left ventricular outflow tract stroke volume (LVOTSV). "
01/01/2015 - "In this double-blind, placebo-controlled study, patients with chronic heart failure were randomized 2:1 to receive omecamtiv mecarbil or placebo in 2 sequential cohorts of escalating doses designed to achieve plasma concentrations previously shown to increase systolic function. "
08/20/2011 - "We undertook a double-blind, placebo-controlled, crossover, dose-ranging, phase 2 trial investigating the effects of omecamtiv mecarbil (formerly CK-1827452), given intravenously for 2, 24, or 72 h to patients with stable heart failure and left ventricular systolic dysfunction receiving guideline-indicated treatment. "
09/01/2008 - "Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452."
10/01/2015 - "Omecamtiv mecarbil is a promising new inotropic agent developed for heart failure that may circumvent such limitations. "
|2.||Left Ventricular Dysfunction
|3.||Systolic Heart Failure
03/01/2012 - "Omecamtiv mecarbil: a promising new drug in systolic heart failure."
01/01/2015 - "Omecamtiv Mecarbil (OM) is a small molecule allosteric effector of cardiac myosin that is in clinical trials for treatment of systolic heart failure. "
08/20/2011 - "We report the first study of the cardiac myosin activator, omecamtiv mecarbil, in patients with systolic heart failure. "
08/20/2011 - "The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial."
01/01/2015 - "Omecamtiv mecarbil is a selective cardiac myosin activator that augments cardiac contractility in patients with systolic heart failure through a dose-dependent increase in systolic ejection time. "
01/01/2015 - "Doses of omecamtiv mecarbil producing plasma concentrations previously shown to increase systolic function were well tolerated during exercise in these study patients with ischemic cardiomyopathy and angina. "
01/01/2015 - "The goal of this study was to assess the safety and tolerability of omecamtiv mecarbil treatment during symptom-limited exercise in patients with ischemic cardiomyopathy and angina. "
01/01/2015 - "(Pharmacokinetics [PK] and Tolerability of Intravenous [IV] and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina; NCT00682565)."
01/01/2015 - "Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina."
08/01/2014 - "Latest trials in trans-aortic valve implantation, heart failure (eplerenone, aliskiren, spironolactone, sildenafil, dopamine, nesiritide, omecamtiv mecarbil, the algisyl left ventricular augmentation device, and echo-guided cardiac resynchronization), atrial fibrillation (edoxaban, dabigatran, and ablation), cardiac arrest (hypothermia, LUCAS™ mechanical chest compression), and cardiovascular prevention (vitamins, renal denervation for resistant hypertension, renal artery stenting, saxagliptin, alogliptin, and gastric banding) are also discussed. "
|3.||Brain Natriuretic Peptide (Natrecor)
|1.||Cardiac Resynchronization Therapy